Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.

被引：0
|
作者：
Kang, Yixin
Zhang, Dianbao
Mi, Youjia
Niu, Xiedong
Kang, Yuan
Xie, Dongjie
Li, Wenyao
Zhang, Ce
Yang, Junqiang
Yao, Jun
机构：
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gastroenterol Oncol, Luoyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16034
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
    Pijnappel, Esther N.
    Dijksterhuis, Willemieke P. M.
    van der Geest, Lydia G.
    de Vos-Geelen, Judith
    de Groot, Jan Willem B.
    Homs, Marjolein Y., V
    Creemers, Geert-jan
    Mohammad, Nadia Haj
    Besselink, Marc G.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (05): : 443 - +
  • [32] Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
    Koutsoukos, Konstantinos
    Bamias, Aristotelis
    Tzannis, Kimon
    Espinosa Montano, Marta
    Bozionelou, Vasiliki
    Christodoulou, Christos
    Stefanou, Dimitra
    Kalofonos, Haralabos
    Duran, Ignacio
    Papazisis, Konstantinos
    ONCOTARGETS AND THERAPY, 2017, 10 : 4885 - 4893
  • [33] A real-world clinical study of camrelizumab in the treatment of esophageal cancer
    Sun, G.
    Peng, W.
    Wang, F.
    Cheng, H.
    Wang, S. Z.
    Xia, L.
    Du, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1318 - S1318
  • [34] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Pranav Abraham
    Joe Gricar
    Ying Zhang
    Veena Shankaran
    Advances in Therapy, 2020, 37 : 3392 - 3403
  • [35] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Abraham, Pranav
    Gricar, Joe
    Zhang, Ying
    Shankaran, Veena
    ADVANCES IN THERAPY, 2020, 37 (07) : 3392 - 3403
  • [36] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [37] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    CANCER MEDICINE, 2024, 13 (09):
  • [38] Real-world study of reasons for non-utilization of second-line treatment in patients with primary biliary cholangitis
    Meloni, Seema T.
    Zein, Claudia O.
    Smither, Allison R.
    Iyengar, Anushree
    Calay, Ediz S.
    Wagner, Tyler E.
    Yenukoti, Rohit K.
    Pommie, Christelle
    Gattolliat, Olivier
    Doban, Vitalii
    Juran, Brian D.
    Lazaridis, Konstantinos N.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S326 - S326
  • [39] ERLOTINIB VS DOCETAXEL AS SECOND-LINE TREATMENT OF ADVANCED NSCLC: A REAL-WORLD COST-EFFECTIVENESS STUDY
    Cromwell, Ian
    Van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1181 - S1182
  • [40] Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
    Nie, Caiyun
    Xu, Weifeng
    Lv, Huifang
    Gao, Xiaohui
    Li, Guofeng
    Chen, Beibei
    Wang, Jianzheng
    Liu, Yingjun
    Zhao, Jing
    He, Yunduan
    Wang, Saiqi
    Chen, Xiaobing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345